SPDR® S&P 600 Small Cap Growth ETF
Key Risks Facing Sucampo Pharmaceuticals in 2017
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017
Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
How Did Cal-Maine Foods Stock React to Its Fiscal 4Q16 Results?
Cal-Maine Foods reported its fiscal 4Q16 results on July 18. There wasn’t impact on the stock price even though the company reported a loss for the quarter.
How Much Did Cal-Maine Return to Shareholders in Fiscal 2016?
Cal-Maine Foods has a dividend yield of 4.0% as of July 18, 2016. Management raised the dividend at a CAGR (compound annual growth rate) of 15.3% over five years.
Analyzing Cal-Maine Foods’ Variable Dividend Policy
Cal-Maine has a variable dividend policy in place. It has a dividend yield of 5.8% as of June 28. Management raised the dividend at a CAGR of 15.3% over five years.
Analysts Have Revised EPS Estimates for B&G Foods: Why?
B&G Foods’ (BGS) earnings estimates have been on an upward trend since its fiscal 1Q16 impressive results. The Green Giant acquisition contributed to the results.
Why Did B&G Foods Stock Fall 10% after Fiscal 4Q15 Results?
With 4Q15 earnings below estimates by 12% and lower-than-expected guidance for 2016, BGS stock fell 10% the next day.